Rallybio Statistics

Total Valuation

Rallybio has a market cap or net worth of $49.74 million. The enterprise value is -$44.10 million.

Market Cap	49.74M
Enterprise Value	-44.10M

Important Dates

The next estimated earnings date is Tuesday, August 6, 2024, before market open.

Earnings Date	Aug 6, 2024
Ex-Dividend Date	n/a

Share Statistics

Rallybio has 41.45 million shares outstanding. The number of shares has increased by 1.30% in one year.

Shares Outstanding	41.45M
Shares Change (YoY)	+1.30%
Shares Change (QoQ)	+0.32%
Owned by Insiders (%)	4.06%
Owned by Institutions (%)	75.82%
Float	23.20M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.56
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.77, with a Debt / Equity ratio of 0.00.

Current Ratio	9.77
Quick Ratio	n/a
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -66.60% and return on invested capital (ROIC) is -89.77%.

Return on Equity (ROE)	-66.60%
Return on Assets (ROA)	-61.50%
Return on Capital (ROIC)	-89.77%
Revenue Per Employee	n/a
Profits Per Employee	-$2.54M
Employee Count	30
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -79.66% in the last 52 weeks. The beta is -1.65, so Rallybio's price volatility has been lower than the market average.

Beta (5Y)	-1.65
52-Week Price Change	-79.66%
50-Day Moving Average	1.64
200-Day Moving Average	2.29
Relative Strength Index (RSI)	34.65
Average Volume (20 Days)	376,418

Short Selling Information

The latest short interest is 1.72 million, so 4.14% of the outstanding shares have been sold short.

Short Interest	1.72M
Short Previous Month	1.76M
Short % of Shares Out	4.14%
Short % of Float	7.41%
Short Ratio (days to cover)	9.04

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-80.35M
Pretax Income	-76.28M
Net Income	-76.28M
EBITDA	-76.13M
EBIT	-76.28M
Earnings Per Share (EPS)	-$1.87

Full Income Statement

Balance Sheet

The company has $94.18 million in cash and $339,000 in debt, giving a net cash position of $93.84 million or $2.26 per share.

Cash & Cash Equivalents	94.18M
Total Debt	339,000
Net Cash	93.84M
Net Cash Per Share	$2.26
Equity (Book Value)	89.16M
Book Value Per Share	2.15
Working Capital	88.46M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$56.96 million and capital expenditures -$12,000, giving a free cash flow of -$56.97 million.

Operating Cash Flow	-56.96M
Capital Expenditures	-12,000
Free Cash Flow	-56.97M
FCF Per Share	-$1.40

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Rallybio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.30%
Shareholder Yield	-1.30%
Earnings Yield	-153.35%
FCF Yield	-114.54%

Analyst Forecast

The average price target for Rallybio is $8.90, which is 641.67% higher than the current price. The consensus rating is "Buy".

Price Target	$8.90
Price Target Difference	641.67%
Analyst Consensus	Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2